Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study
- PMID: 18378544
- DOI: 10.1634/theoncologist.2007-0159
Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study
Abstract
Objective: Bone metastases are a major cause of morbidity in cancer patients. Treatment includes bisphosphonates, which are also associated with avascular osteonecrosis of the jaw (ONJ). Our aim was to evaluate the correlation between bisphosphonates and ONJ.
Patients and methods: Of the 539 patients with bone metastases treated in our department from June 2002 to December 2006 with i.v. bisphosphonates, eight (1.5%) developed ONJ.
Results: The eight patients with ONJ had all been given zoledronic acid, and two had also been treated with pamidronic acid. In four of the patients, ONJ was diagnosed during treatment, while in the remaining four it was diagnosed several months after therapy with bisphosphonates had ended. Six of these patients received local noninvasive treatment, of whom five progressed. Two showed apparent autolimitation of the disease. The remaining two patients underwent surgical resection and currently show no signs of relapse. All eight ONJ patients presented with various concomitant risk factors such as paradontopathy, dental extraction, or spontaneous avulsion.
Conclusions: Our results show that ONJ can appear months after interruption of treatment and that a surgical approach can be used in suitable cases. Closer cooperation is needed among specialists to define guidelines for the prevention of ONJ in patients with bone metastases.
Similar articles
-
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.J Clin Oncol. 2005 Dec 1;23(34):8580-7. doi: 10.1200/JCO.2005.02.8670. J Clin Oncol. 2005. PMID: 16314620
-
A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.Clin Ther. 2007 Aug;29(8):1548-58. doi: 10.1016/j.clinthera.2007.08.008. Clin Ther. 2007. PMID: 17919538 Review.
-
Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies.Gynecol Oncol. 2009 Mar;112(3):605-9. doi: 10.1016/j.ygyno.2008.11.029. Epub 2009 Jan 12. Gynecol Oncol. 2009. PMID: 19136147
-
Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.Eur Urol. 2008 Nov;54(5):1066-72. doi: 10.1016/j.eururo.2008.06.070. Epub 2008 Jun 26. Eur Urol. 2008. PMID: 18602738
-
Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases.J Oral Pathol Med. 2005 Feb;34(2):120-3. doi: 10.1111/j.1600-0714.2004.00269.x. J Oral Pathol Med. 2005. PMID: 15641993 Review.
Cited by
-
Autologous bone marrow stem cell intralesional transplantation repairing bisphosphonate related osteonecrosis of the jaw.Head Face Med. 2011 Aug 17;7:16. doi: 10.1186/1746-160X-7-16. Head Face Med. 2011. PMID: 21849044 Free PMC article.
-
Prevalence of bisphosphonate-associated osteonecrosis of the jaw after intravenous zoledronate infusions in patients with early breast cancer.Clin Oral Investig. 2014;18(2):401-7. doi: 10.1007/s00784-013-1012-5. Epub 2013 Jun 10. Clin Oral Investig. 2014. PMID: 23749244 Clinical Trial.
-
Ten-year experience of the multidisciplinary Osteoncology Center.Support Care Cancer. 2019 Sep;27(9):3395-3402. doi: 10.1007/s00520-019-4635-5. Epub 2019 Jan 16. Support Care Cancer. 2019. PMID: 30649614
-
Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw.Oncologist. 2011;16(1):121-32. doi: 10.1634/theoncologist.2010-0183. Epub 2011 Jan 6. Oncologist. 2011. PMID: 21212433 Free PMC article.
-
The incidence and relative risk of adverse events in patients treated with bisphosphonate therapy for breast cancer: a systematic review and meta-analysis.Ther Adv Med Oncol. 2019 Jun 9;11:1758835919855235. doi: 10.1177/1758835919855235. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31217825 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical